Thank you for your interest. The I-MOVE+ project (2015-2018) is over, and this website will no longer be updated. However, activities to monitor vaccine effectiveness in Europe are ongoing and can be found on the I-MOVE and SpiDnet websites for influenza (coming soon) and pneumococcal vaccines (https://sites.google.com/a/epiconcept.fr/ipd-surveillance/) assessment of vaccine effectiveness and impact against influenza and pneumococcal disease. Furthermore, these protocols will be applied in registry-based studies in order to contribute to the deliverables in WP2 (influenza vaccines) and WP3 (pneumococcal vaccines). Hence, the work in WP4 will be coordinated with the work in WP2 and WP3 to agree on a joint interpretation of the outcomes from the various studies. Finally, the aim is also to provide figures that can contribute to estimation of cost-effectiveness (WP5). Leader: Statens Serum Institut Participants:
Access to restricted area for Work Package 4 I-MOVE+ Generic Register-based protocols to measure influenza vaccine effectiveness :
(Study site specific protocols are available upon request) |